Viral vaccines

Our viral vaccine capabilitiess include generation, production, purification and analysis of DNA and RNA viruses manufactured on mammalian cell lines.

Our contribution to Global Health

In pursuit of increasing global vaccination coverage, we are committed to develop technologies that substantially lower the cost of vaccine manufacturing. Hereto, we develop highly intensified production process for viral vaccines, HIP-Vax, to reduce cost of product by decreasing CAPEX and cost of goods. Furthermore, we have developed SCOUT® technology to reduce development timelines and time to market. As it is known that costs of capital (53%) and cost of failure (40%) are the biggest cost attributes to a vaccine price paid by consumers, our platforms substantially aid global health initiatives to reach their goals.

Viral vaccines track record

We have extensive experience in manufacturing a wide range of viruses including polio, measles, rubella, influenza and rotavirus. We are proud to have delivered vaccine products for phase-I and phase-II clinical studies in both the EU and US markets. Our experience in the field, anchored in production, purification, and testing protocols, has resulted in a successful track record in delivering vaccine products. For example, in a collaboration with PATH, we have manufactured GMP virus stocks of several novel oral polio vaccine strains. In addition, in collaboration with Prof. Marcellus Ubbink (Leiden University, Netherlands) we are developing a very promising new class of vaccines: self-adjuvating, thermostable influenza vaccines.

The projects that we have done with Batavia were both technically and logistically challenging, but owing to their in-depth know-how and experience in working with viruses, have been very successful. The staff members at Batavia display great ownership in delivering on their commitments.

John KonzProject Director, PATH

Together with Batavia Biosciences, under a grant from the TTW (Applied and Engineering Sciences) domain of the Netherlands Organization for Scientific Research (NWO), we are jointly developing novel influenza vaccines. This is a very exciting program and requires intimate collaboration, because the program involves a public – private training module. I am enthusiastic about the collaboration, because such projects between the University and a research-oriented company like Batavia are the way for scientific insights to find useful applications in society.

Prof. Marcellus Ubbink,Leiden University

We’re proud to call Batavia Biosciences an IAVI collaborator since 2012 as both organizations share a common goal to develop vaccines that are affordable and accessible to address infectious disease globally. Batavia has been instrumental in the development of cell lines, process, and analytics to support IAVI’s manufacturing and development of HIV vaccine viral vectors, in particular for the vesicular stomatitis virus (VSV) platform for clinical testing. Building on this experience, IAVI and Batavia are extending this innovative collaboration to include use of the VSV platform for the development of vaccines for other emerging infectious diseases that disproportionately affect people living in poverty.

Mark Feinberg, M.D., Ph.DIAVI President and CEO

Viral vaccines technologies

HIP-Vax for low-cost viral vector and vaccine manufacturing

HIP-Vax technology®

Under the HIP-Vax® brand, we market our process development services and know-how which enables fast and low-cost vaccine manufacturing using bioprocess intensification technologies.

Learn more
SATIRN® technology

SATIRN® technology

The SATIRN® technology delivers a platform to manufacture potent, self-adjuvating, thermostable, membrane protein-based vaccines.

Learn more

SCOUT® technology

The SCOUT® technology provides for an effective tool for “Design-of-Experiments” (DoE) approaches. It uses a miniaturized production and purification platform to rapidly develop multivariate processes.

Learn more

Process development

We develop scalable, robust and GMP-compliant manufacturing processes for viral vaccines.

Upstream process development

We deliver scalable and robust GMP-compliant processes for viral vaccines.

Learn more

Downstream process development

We deliver scalable and robust GMP-compliant processes for viral vaccines.

Learn more

Analytical development

We perform and develop all the required product-specific release and stability assays for your viral vaccine.

Learn more

In silico cost modeling

We often perform in silico cost modeling of manufacturing processes for viral vaccines.

Learn more

Related resources

Driving down COGs of viral vector-based biopharmaceuticals

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
How do you keep cost of goods (COGs) for viral vector-based medicines within reason to develop a product that is both affordable and financially viable?  In this 3-part series we…
adenoviral vector product from bench to clinic

Taking your adenoviral vector product from R&D to the clinic

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
Adenoviruses have been shown to be very effective vehicles for delivering genetic material to cells and are therefore in demand to develop gene therapies and vaccine products. The road from…
Adenovirus vectors gene therapy and vaccine development

Adenovirus vectors: cutting edge delivery vehicles for gene therapy and vaccine development

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
Adenovirus (Ad) vectors are used to develop gene therapy products and vaccines. Decades of research stand behind these vectors which have gone through several iterations and improvements to make them…
Past and current challenges of adenoviral vector platforms

Adenoviral vector platform: past and current challenges

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
Adenoviruses have been explored for gene therapy purposes for many decades. They are DNA viruses, with a double-stranded DNA genome of around 26-45 kilobases. Adenoviruses have been isolated from a…
Process development
Preclinical manufacturing
Knowledge center

Talk to our experts

Alfred Luitjens - Bioprocess expert
Alfred Luitjens

Global Technical Sales Director
+31 (0) 88 9950600

Send us a message